---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-091674"
form_type: "8-K"
ticker: "TOVX"
cik: "0000894158"
company_name: "Theriva Biologics, Inc."
filed_at: "2026-08-06T12:10:35+00:00"
generated_at: "2026-08-06T12:15:27.143298+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Theriva Biologics doses first patient in VIRAGE2 Phase 2a trial of VCN-01 in metastatic PDAC

## Summary
- First patient dosed in VIRAGE2 Phase 2a trial evaluating more frequent repeated dosing of VCN-01 in first-line metastatic PDAC.
- Enrollment completion expected H2 2026; initial pharmacodynamic and safety/tolerability data anticipated by Q3 2027.
- Trial based on VIRAGE Phase 2b data where 2 doses of VCN-01 + SoC showed improved overall survival, progression-free survival, and duration of response vs SoC alone.
- EMA and FDA feedback recognized potential of repeated VCN-01 dosing to improve clinical outcomes.
- Results will inform dosing regimen for potential future pivotal Phase 3 trial.

## SEC filing metadata
- accession: 0001104659-26-091674
- form_type: 8-K
- ticker: TOVX
- cik: 0000894158
- company_name: Theriva Biologics, Inc.
- filed_at: 2026-08-06T12:10:35+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/894158/000110465926091674/0001104659-26-091674-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/894158/000110465926091674/tm2622359d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-091674
- JSON: https://secwatch.observer/filing/0001104659-26-091674.json
- Plain text: https://secwatch.observer/filing/0001104659-26-091674.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.